CVRx (CVRX) Projected to Post Earnings on Thursday

CVRx (NASDAQ:CVRX) is projected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $15.75 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

CVRx Price Performance

CVRX stock opened at $6.69 on Wednesday. The company has a current ratio of 9.62, a quick ratio of 8.60 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $175.34 million, a P/E ratio of -3.31 and a beta of 1.31. The business has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $8.14. CVRx has a twelve month low of $4.30 and a twelve month high of $15.41.

Hedge Funds Weigh In On CVRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alliancebernstein L.P. increased its position in shares of CVRx by 10.7% in the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after buying an additional 1,700 shares in the last quarter. Cresset Asset Management LLC grew its stake in CVRx by 3.5% in the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock valued at $315,000 after acquiring an additional 1,823 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in CVRx by 7.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 57,447 shares of the company’s stock valued at $464,000 after acquiring an additional 3,804 shares in the last quarter. Bridgeway Capital Management LLC raised its position in CVRx by 8.9% during the third quarter. Bridgeway Capital Management LLC now owns 54,000 shares of the company’s stock worth $436,000 after acquiring an additional 4,400 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in shares of CVRx by 7.6% in the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock valued at $524,000 after purchasing an additional 6,312 shares in the last quarter. Institutional investors and hedge funds own 75.27% of the company’s stock.

Analysts Set New Price Targets

CVRX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of CVRx in a research note on Monday, December 29th. Canaccord Genuity Group increased their target price on shares of CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Cantor Fitzgerald raised their price target on CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.40.

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.